Kamat - Figure 4
Why is this important?
FIG. 4: Reported initial response rates to BCG are high. For carcinoma in situ (CIS), these approach 80% and the tumor-free rates for papillary disease approach as high as 70%. However, some patients do not derive benefit from BCG therapy, and, over time, many tumors relapse.